Artimplant Receives Approval to Market Artelon(R) TMC Spacer in Australia.

STOCKHOLM, Sweden -- The Swedish biomaterials company Artimplant (STO:ARTIB) receives approval to market the Artelon(R) TMC Spacer in Australia. The distribution network of Small Bone Innovations will market the product.

Artelon(R) TMC Spacer for treatment of thumb base osteoarthritis 

Artelon(R) TMC Spacer is an implant for treatment of thumb base osteoarthritis (OA). The Artelon(R) Spacer is preserving the bone anatomy of the hand and is buffering the bone on bone contact that results from osteoarthritic joint degeneration. Compared to current therapy it has the following benefits.

--Significantly better grip strength compared to tendon interposition arthroplasty

--Stable joints, no subluxations

--Reduced pain

--Fast and easy procedure, no general anesthesia required

--Tissue preserving approach - minimal tissue resection of the trapezial bone results in intact anatomy

Successful study

A pilot study with Artelon(R) Spacer for treatment of OA in the base of the thumb conducted by Artimplant has been published in the March 2005 issue of American Journal of Hand Surgery. The results from the study show that patients with the Artelon(R) Spacer experienced significantly better grip strength compared to a control group of patients treated with tendon interposition arthroplasty.

Artelon(R) - a unique biomaterial

The Artelon(R) TMC Spacer is made of Artelon(R), a unique long-term degradable biomaterial that acts as a temporary scaffold to facilitate formation of new host tissue. Due to its versatility and unique combination of

properties - long-term degradation, mechanical properties similar to human tendons and excellent biocompatibility in hard and soft tissue - Artelon(R) offers new solutions to unmet clinical needs in several therapy areas.

Artimplant has also posted the following press releases the last six months on www.artimplant.com

--Artimplant is establishing office in the USA

--Artimplant fulfils six out of seven goals of 2005 and builds distributor network within odontology 

--Artelon(R) implant for rotator cuff reinforcement receives CE-mark

--Artimplant and ArthroCare Corporation sign distribution agreement for North America

--Artelon(R) nanofibers successfully used as coating on metal implants

--Artimplant signs four new development and license agreements with Small Bone Innovations

--Artimplant receives CE-mark for Artelon(R) Surgical Suture

--Artimplant expands its long-term degradable Artelon(R) Surgical Suture product range

--New study shows that Artelon(R) works as a dermal filler

--Artimplant expand the field of application for Artelon(R)

--Artimplant employs Ms. Susanne Hamilton as Product Manager Odontology

--Artimplant appoints Lars-Johan Cederbrant as Chief financial Officer

--Electrospinning of Artelon(R) in collaboration with IFP Research and Chalmers University of Technology expand the opportunities for Artimplant

--Artimplant boosts its commercial base through CE-mark for two new products within odontology and craniomaxillofacial surgery

About Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic, odontological and reconstructive surgery. The Company is engaged in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The proprietary technology Artelon(R), a long-term degradable biomaterial, offers new solutions to unmet clinical needs and opens new markets. Artimplant's business model is that of licensing its products and technology to global partners. The Company currently has six licensing agreements with two global partners. Artimplant is a public company, listed on the Stockholm Stock Exchange, O-list.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This information was brought to you by Waymaker http://www.waymaker.net